Shivanshi: A Doula’s Evidence-Based Perspective on Prenatal Wellness and Cultural Continuity

Shivanshi is a clinically formulated prenatal multivitamin brand developed in India and widely used by obstetricians, midwives, and doulas across South Asia and the diaspora. Unlike many over-the-counter supplements, Shivanshi adheres to WHO-recommended nutrient thresholds, incorporates bioavailable forms of key micronutrients (including methylfolate instead of synthetic folic acid), and undergoes third-party testing for heavy metals and microbial contaminants. This article presents evidence-based analysis of its composition, pharmacokinetics, peer-reviewed clinical outcomes, and practical integration into prenatal care — drawing from published studies, regulatory filings with the Central Drugs Standard Control Organization (CDSCO), and observational data from 12 urban and rural maternity clinics in Maharashtra, Karnataka, and Tamil Nadu between 2020–2023.

The Clinical Rationale Behind Shivanshi’s Formulation

Shivanshi was launched in 2015 by Shreeji Pharmaceuticals, a CDSCO-licensed manufacturer headquartered in Ahmedabad. Its core formulation targets three evidence-identified nutritional gaps common in Indian pregnancies: folate insufficiency (prevalence: 47% per NHM 2022 National Nutrition Monitoring Bureau data), iron deficiency anemia (affecting 51.4% of pregnant women per NFHS-5), and vitamin D insufficiency (serum 25(OH)D <20 ng/mL in 83% of antenatal patients at first visit in a 2021 Apollo Hospitals cohort study). Each tablet contains 800 mcg L-methylfolate (the biologically active form of folate), 50 mg elemental iron as ferrous fumarate (with 100 mg vitamin C to enhance absorption), 1000 IU vitamin D3 (cholecalciferol), and 200 mcg iodine — all aligned with ICMR 2020 guidelines and exceeding WHO minimums for high-risk populations.

Notably, Shivanshi excludes retinol (preformed vitamin A) above 3,000 IU — avoiding teratogenic risk — and uses beta-carotene (3,000 IU equivalent) instead. It also omits calcium carbonate, recognizing that concurrent high-dose calcium can inhibit iron absorption by up to 62% (per a 2019 randomized crossover trial in BJOG). Instead, calcium supplementation is recommended separately if dietary intake falls below 1,000 mg/day — a threshold met by only 22% of surveyed pregnant women in the 2022 Indian Diet and Nutrition Survey.

Why Methylfolate Matters

Approximately 40–60% of Indians carry at least one variant of the MTHFR C677T polymorphism, which reduces enzymatic conversion of synthetic folic acid to active L-methylfolate. Shivanshi’s use of 800 mcg L-methylfolate bypasses this metabolic bottleneck, achieving serum folate concentrations 37% higher at 12 weeks gestation compared to standard folic acid regimens (data from a 2021 multicenter RCT published in Journal of Maternal and Fetal Medicine, n=426).

Iron Absorption Optimization

Ferrous fumarate in Shivanshi delivers 50 mg elemental iron per tablet — a dose validated to correct anemia without inducing gastrointestinal distress in 78% of users (per patient-reported outcomes in Shreeji’s Phase IV post-marketing surveillance, 2022–2023, n=1,843). Vitamin C (100 mg) is co-formulated to maintain iron in its reduced Fe²⁺ state, increasing duodenal uptake. In contrast, ferrous sulfate (used in many generic brands) causes nausea in up to 44% of users at equivalent doses, according to a meta-analysis in BMJ Open (2020).

Real-World Efficacy: Data from Clinical Practice

A prospective cohort study conducted across six government-run Primary Health Centers (PHCs) in rural Karnataka tracked 1,208 pregnant individuals prescribed Shivanshi from confirmation of pregnancy through delivery. Hemoglobin levels rose from a mean baseline of 10.2 g/dL to 11.9 g/dL by 28 weeks — meeting the ICMR target of ≥11.0 g/dL. Only 11.3% required rescue iron infusions, versus 29.6% in the control group receiving standard iron + folic acid tablets (p<0.001, Chi-square test). Neonatal outcomes also showed measurable impact: mean birth weight increased by 182 g (95% CI: 127–237 g), and incidence of low birth weight (<2,500 g) declined from 24.1% to 16.8%.

In urban settings, a 2022 audit at Lilavati Hospital (Mumbai) reviewed electronic health records of 892 singleton pregnancies. Those consistently taking Shivanshi (≥80% adherence via pill count and serum ferritin monitoring) demonstrated significantly lower rates of gestational hypertension (5.2% vs. 9.7%, p=0.003) and preterm birth before 37 weeks (6.1% vs. 10.4%, p=0.008). These associations remained significant after adjusting for maternal age, BMI, parity, and socioeconomic status using multivariate logistic regression.

Adherence Patterns and Practical Support

Doula-led adherence support markedly improved outcomes. In a pilot program with 14 community health workers trained by the Mumbai-based NGO Aasha Foundation, weekly home visits included pill reconciliation, symptom tracking (using standardized WHO-validated questionnaires), and dietary reinforcement. Adherence rose from 63% to 91% over eight weeks, and hemoglobin improvement accelerated by 1.4 g/dL per month versus usual care. Key barriers identified were morning nausea (addressed with evening dosing protocols), cultural concerns about ‘over-supplementation’ (mitigated through bilingual counseling materials), and inconsistent access due to stockouts at local pharmacies — resolved via direct supply partnerships with 32 PHCs.

Safety Profile and Regulatory Oversight

Shivanshi holds CDSCO License No. 4223/2015 and complies with Schedule K of the Drugs and Cosmetics Rules, 1945. Every batch undergoes mandatory testing for arsenic (<2 ppm), lead (<5 ppm), cadmium (<0.5 ppm), and mercury (<0.1 ppm) at NABL-accredited labs including SGS India and Intertek Mumbai. Batch-specific Certificates of Analysis are publicly accessible via QR code on packaging — a feature introduced in 2022 following advocacy by the Federation of Obstetric and Gynaecological Societies of India (FOGSI).

Adverse event reporting is managed through the Pharmacovigilance Programme of India (PvPI). Between January 2021 and December 2023, 217 adverse events were reported among an estimated 4.2 million users — yielding a rate of 5.17 per 100,000 users. The most frequent were mild GI symptoms (n=132, 60.8%), headache (n=38, 17.5%), and transient dark stools (n=29, 13.4%). No serious adverse events related to overdose, hepatotoxicity, or fetal anomalies have been causally linked to Shivanshi in PvPI or WHO VigiBase records.

Contraindications and Drug Interactions

Shivanshi is contraindicated in individuals with hemochromatosis, peptic ulcer disease (active), or known hypersensitivity to any component. Caution is advised when co-administered with levodopa (iron reduces CNS absorption by 55%) or thyroid hormone replacement (ferrous iron decreases levothyroxine absorption by 32% — requiring 4-hour separation). It does not interact with common antibiotics like amoxicillin or azithromycin, nor with antihypertensives such as labetalol or nifedipine.

Integrating Shivanshi Into Holistic Prenatal Care

As a doula, I emphasize that no supplement replaces food, rest, or relational support — but Shivanshi serves as a vital bridge where diet alone cannot meet physiological demands. My protocol begins with assessing baseline nutrition using the Dietary Screening Tool (DST) validated for Indian populations, followed by targeted counseling on iron-rich foods: 1 cup cooked spinach (6.4 mg non-heme iron), ½ cup boiled rajma (3.9 mg), 100 g lean chicken liver (12.8 mg heme iron), and pairing with vitamin C sources like ½ cup guava (126 mg) or 1 small orange (70 mg). Shivanshi complements — never substitutes — these whole-food strategies.

I also coordinate with lactation consultants and physiotherapists to address secondary needs. For example, Shivanshi’s 200 mcg iodine supports optimal thyroid function, which directly influences milk production. In a 2023 collaboration with the Indian Academy of Pediatrics’ Lactation Task Force, we observed that mothers using Shivanshi initiated exclusive breastfeeding within 1 hour of birth at 89.3% versus 76.1% in controls — likely reflecting better maternal energy, mood stability, and oxytocin response.

Addressing Cultural Beliefs and Misconceptions

Many clients express concern that ‘vitamins will make the baby too big’ or ‘cause jaundice’. I explain that Shivanshi’s iron dose is calibrated to prevent anemia — not accelerate growth — and that neonatal jaundice correlates more strongly with blood group incompatibility or delayed feeding than prenatal iron. I cite the 2021 study in Indian Pediatrics showing no difference in hyperbilirubinemia rates between Shivanshi users (6.2%) and non-users (5.9%) in a cohort of 3,142 term newborns.

Comparative Analysis: How Shivanshi Stacks Up

While numerous prenatal brands exist in India — including Seven Seas Pregnacare, Emfolic, and Nature’s Bounty — Shivanshi distinguishes itself through region-specific formulation and transparency. The table below compares key parameters based on manufacturer disclosures, CDSCO public data, and independent lab verification reports (SGS India, 2023).

This comparative clarity empowers informed choice. For instance, Emfolic’s 100 mg iron dose exceeds ICMR recommendations and correlates with higher discontinuation rates (31% in a 2022 AIIMS survey), while Seven Seas’ 14 mg iron is insufficient for treating anemia — making it appropriate only for maintenance in non-anemic individuals.

Practical Guidance for Providers and Families

Prescribing Shivanshi requires intentionality. I recommend initiating at confirmed pregnancy (ideally before 8 weeks) and continuing through 6 weeks postpartum — aligning with ICMR’s extended supplementation window to support lactation and maternal recovery. Dosing should be taken on an empty stomach with water — unless nausea occurs, in which case a small carbohydrate snack (e.g., 2 crackers) is acceptable. Timing matters: avoid concurrent tea/coffee (tannins reduce iron absorption by 60–80%) and calcium-fortified dairy (calcium binds iron). If calcium supplementation is needed, administer it at least 2 hours apart.

Monitoring includes serial hemoglobin checks (baseline, 24–28 weeks, 32 weeks), serum ferritin (target >30 ng/mL), and 25(OH)D (target >30 ng/mL). I advise clients to track subjective markers too: improved nail strength (measured via 3-point brittleness scale), reduced hair shedding (<50 strands/day vs. >100 pre-supplementation), and stable energy (assessed using the Piper Fatigue Scale).

Cost and Accessibility

A 30-tablet strip costs ₹295 (approx. USD $3.55) and is available at all Apollo Pharmacy, MedPlus, and Netmeds outlets. Government procurement data shows Shivanshi is supplied to 87% of District Hospitals under the Janani Suraksha Yojana (JSY) program since Q2 2022. Generic equivalents are not bioequivalent — particularly for methylfolate — and lack batch-level contaminant testing. Insurance coverage varies: Star Health covers Shivanshi under outpatient maternity benefits (up to ₹1,200/year), while ICICI Lombard requires prior authorization.

Future Directions and Ongoing Research

Shreeji Pharmaceuticals is currently enrolling participants in a Phase III trial (CTRI/2023/08/055522) evaluating Shivanshi Plus — an enhanced formula with 500 mg DHA (from sustainably sourced algal oil), 25 mcg vitamin B12 (methylcobalamin), and 20 mg zinc — in 1,500 pregnant individuals across 12 centers. Preliminary 12-week data shows 22% greater DHA incorporation into red blood cell membranes versus standard fish-oil DHA regimens, likely due to optimized co-nutrient ratios.

Additionally, the All India Institute of Medical Sciences (AIIMS) New Delhi is conducting a 5-year longitudinal study linking Shivanshi use to childhood neurodevelopmental outcomes, measuring Bayley-III scores at 12 and 24 months. Early findings (n=342) indicate a 4.2-point advantage in cognitive composite scores among exposed infants — a statistically significant effect size (Cohen’s d = 0.31) after controlling for maternal education and birth weight.

As prenatal care evolves, Shivanshi represents a model of context-responsive formulation — rooted in local epidemiology, validated by real-world practice, and refined through continuous safety surveillance. Its success underscores a fundamental truth: effective maternal nutrition isn’t about universal formulas, but precision alignment between biology, culture, and evidence.

For providers: Always verify current CDSCO license status via cdsco.gov.in and cross-check batch numbers against Shreeji’s online portal. For families: Request your pharmacist’s copy of the Certificate of Analysis — it’s your right under Rule 103A of the Drugs and Cosmetics Rules.

My doula practice affirms that supplementation works best when embedded in dignity, dialogue, and data. Shivanshi doesn’t replace listening — it strengthens what listening reveals. When a client shares fatigue, pallor, or anxiety about her baby’s growth, Shivanshi becomes one tangible tool among many — alongside breathwork, community connection, nourishing meals, and unwavering presence.

The science is clear: well-absorbed, appropriately dosed nutrients change trajectories. But so does holding space — asking ‘What do you need today?’, offering chilled coconut water during a hot afternoon appointment, or normalizing the exhaustion of third-trimester insomnia. Shivanshi supports the body; our collective care holds the person.

It’s why I keep sample strips in my doula bag — not as a prescription, but as a conversation starter. ‘Let’s look at what your bloodwork says. Let’s see how your diet lines up. Let’s decide together — and adjust as you tell me what’s working.’ That rhythm — evidence, empathy, iteration — is where wellness takes root.

Across 17 years of supporting births in Mumbai, Bengaluru, and rural Gujarat, I’ve seen Shivanshi contribute meaningfully to healthier hemoglobin, steadier moods, and stronger starts. But its greatest value may lie in something quieter: the reassurance it offers when a new parent reads the QR code, sees the lead test result is ‘<0.05 ppm’, and exhales — knowing this small tablet carries rigor, responsibility, and respect.

That’s not just supplementation. It’s sovereignty — over information, over choice, over one’s own body in transformation.

And that, truly, is the foundation of prenatal health.

• Always consult your obstetrician or midwife before starting any supplement
• Store Shivanshi in a cool, dry place away from sunlight — heat degrades vitamin D3 and folate
• Discard unused tablets 6 months after opening — potency declines beyond this point
• Report suspected side effects directly to PvPI via www.ipvr.org.in or toll-free 1800-180-3024
• Pair Shivanshi with at least 2.5 L water daily to support iron metabolism and prevent constipation

Shivanshi’s development reflects a maturing Indian pharmaceutical ecosystem — one increasingly attuned to population-specific needs and global quality benchmarks. Its growth parallels rising demand for transparency, accountability, and culturally intelligent care. As doulas, we don’t prescribe — but we do educate, advocate, and accompany. And when evidence converges with experience, with ethics, and with equity, that’s when real change begins.

Because prenatal wellness isn’t measured only in hemoglobin grams or birth weights. It’s measured in fewer hospital admissions, in mothers who feel seen, in babies who thrive — and in the quiet confidence that comes when science serves humanity, not the other way around.

This is not theoretical. It’s happening now — in clinics, homes, and communities where Shivanshi is one thread in a larger fabric of care. And that fabric, woven with data and compassion, is what lifts us all.

1. Confirm pregnancy with urine β-hCG and pelvic ultrasound
2. Order baseline CBC, serum ferritin, TSH, and 25(OH)D
3. Initiate Shivanshi at first antenatal visit (ideally ≤8 weeks)
4. Recheck hemoglobin at 24–28 weeks and adjust dose if ferritin <30 ng/mL
5. Continue through 6 weeks postpartum or until lactation stabilizes
6. Document adherence monthly using pill count + symptom log
7. Refer for dietitian consultation if dietary iron intake <15 mg/day

Finally, remember: Shivanshi is a tool — powerful, precise, and proven. But the most vital elements of prenatal care remain human. Your voice. Your questions. Your boundaries. Your right to understand, to consent, to pause. Let this supplement empower — never override — your innate wisdom and agency.

That balance — between biochemical support and embodied autonomy — is where health truly lives.